Mergers & Acquisitions Mergers & Acquisitions

Novo Holdings-Catalent deal could negatively impact pharma companies, Eli Lilly tells Brazilian regulator

By Flavia Fortes
  • 26 Aug 2024 19:02
  • 26 Aug 2024 19:02
Eli Lilly told the Brazilian competition authority that the acquisition of Catalent by Novo Holdings could impact pharmaceutical companies that depend on the drug manufacturer’s services.
“Catalent serves a broad range of pharmaceutical and biotechnology companies of all sizes (including 87 of the top 100 branded pharmaceutical and consumer health

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Flavia Fortes

Global Head of Mergers


Flavia writes about merger control, antitrust enforcement and litigation in the U.S. and Brazil. Before joining MLex, Flavia worked as an Antitrust Consultant in the Federal Trade Commission's Office of International Affairs and as a Research Fellow for the American Antitrust Institute. She has written on the intersection of antitrust law and intellectual property law in technology-driven and innovative markets.

Discover MLex

Stay on top of global regulatory developments

Latest News